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The outer membrane (OM) of Gram-negative bacteria is a highly selective permeability
barrier due to its asymmetric structure with lipopolysaccharide (LPS) in the outer leaflet.
In Escherichia coli, LPS is transported to the cell surface by the LPS transport (Lpt)
system composed of seven essential proteins forming a transenvelope bridge. Transport
is powered by the ABC transporter LptB2FGC, which extracts LPS from the inner
membrane (IM) and transfers it, through LptC protein, to the periplasmic protein LptA.
Then, LptA delivers LPS to the OM LptDE translocon for final assembly at the cell
surface. The Lpt protein machinery operates as a single device, since depletion of any
component leads to the accumulation of a modified LPS decorated with repeating units
of colanic acid at the IM outer leaflet. Moreover, correct machine assembly is essential
for LPS transit and disruption of the Lpt complex results in LptA degradation. Due to
its vital role in cell physiology, the Lpt system represents a good target for antimicrobial
drugs. Thanatin is a naturally occurring antimicrobial peptide reported to cause defects
in membrane assembly and demonstrated in vitro to bind to the N-terminal β-strand of
LptA. Since this region is involved in both LptA dimerization and interaction with LptC,
we wanted to elucidate the mechanism of inhibition of thanatin and discriminate whether
its antibacterial effect is exerted by the disruption of the interaction of LptA with itself or
with LptC. For this purpose, we here implemented the Bacterial Adenylate Cyclase Two-
Hybrid (BACTH) system to probe in vivo the Lpt interactome in the periplasm. With this
system, we found that thanatin targets both LptC–LptA and LptA–LptA interactions, with
a greater inhibitory effect on the former. We confirmed in vitro the disruption of LptC–
LptA interaction using two different biophysical techniques. Finally, we observed that in
cells treated with thanatin, LptA undergoes degradation and LPS decorated with colanic
acid accumulates. These data further support inhibition or disruption of Lpt complex
assembly as the main killing mechanism of thanatin against Gram-negative bacteria.
Keywords: bacterial cell wall, lipopolysaccharide, Lpt system, thanatin, antimicrobial peptides, BACTH
technique, NMR
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INTRODUCTION
The emergence and spread of multidrug resistant pathogens
pose an alarming threat to human and animal health worldwide.
The old classes of antibiotics are becoming ineffective at
killing an increasing number of pathogens and the decline in
the discovery and development of new drugs, experienced in
recent years, is seriously eroding the ability of clinicians to
control infectious diseases, making the identification of new
antimicrobial compounds with novel mechanisms of action an
urgent need (Tacconelli et al., 2018). This situation is even more
worrisome for Gram-negative pathogens since they are endowed
with an asymmetric outer membrane (OM), surrounding
the inner membrane (IM) and delimiting a peptidoglycan-
containing periplasmic space, that protects them from harmful
hydrophobic compounds such as antibiotics (Nikaido, 2003).
The peculiar permeability barrier properties of the OM are
conferred by the presence of a layer of tightly packed molecules of
lipopolysaccharide (LPS) in its outer leaflet (Raetz and Whitfield,
2002; Silhavy et al., 2010). LPS consists of three covalently
linked moieties: lipid A, the conserved hydrophobic anchor of
the molecule in the membrane; a core oligosaccharide; and
a somewhat variable polysaccharide chain, termed O antigen
(Raetz and Whitfield, 2002). The biosynthesis of the lipid A-core
domain takes place at the cytoplasmic side of the IM, whereas the
assembly of mature LPS occurs at the periplasmic side of the IM,
after flipping of the lipid A-core across the IM by the essential
transporter MsbA (Polissi and Georgopoulos, 1996; Raetz and
Whitfield, 2002; Doerrler et al., 2004).
Translocation of LPS from the IM to the OM, across the
periplasm, requires the activity of the LPS transport (Lpt)
machinery. This assembly is a conserved multiprotein complex
composed, in Escherichia coli, of seven essential proteins (LptA-
G) that bridges the IM and OM (Wu et al., 2006; Sperandeo et al.,
2007, 2008; Ruiz et al., 2008; Freinkman et al., 2012) (Figure 1A).
The Lpt partners are organized in three sub-complexes, located
in each cell envelope compartment (IM, periplasm, and OM),
that interact with each other to allow the transport of LPS to
the OM, shielding the hydrophobic moieties of lipid A in the
hydrophilic environment of the periplasm (Sperandeo et al.,
2008). At the IM, the ABC transporter LptB2FGC provides the
energy for LPS extraction from the IM (Okuda et al., 2012; Li
et al., 2019; Owens et al., 2019). The unconventional subunit
LptC plays a dual role in the transporter, regulating the ATPase
activity and providing the docking site for the periplasmic protein
LptA at the membrane (Sperandeo et al., 2011; Owens et al.,
2019). After extraction, LPS is transferred from LptC to LptA
(Tran et al., 2010; Okuda et al., 2012), that then interacts at the
OM with the periplasmic domain of LptD forming the bridge
that connects the IM and OM (Okuda et al., 2016). LptA has
the tendency to oligomerize in vitro (Suits et al., 2008; Merten
et al., 2012; Santambrogio et al., 2013); however, the number
of LptA monomers that constitute the Lpt bridge is still not
known. At the OM, the translocon composed of the β-barrel
protein LptD and the lipoprotein LptE receives LPS from LptA
for its final assembly at the cell surface (Freinkman et al., 2011;
Dong et al., 2014; Qiao et al., 2014). The interaction between
the Lpt proteins is crucial in building a functional machinery
(Sperandeo et al., 2011; Falchi et al., 2018) and is mediated
by a conserved domain with a peculiar structural architecture
(the β-jellyroll fold) shared by all the periplasmic domains of
the Lpt proteins (LptF, LptG, LptC, LptA, and LptD) (Suits
et al., 2008; Tran et al., 2010; Qiao et al., 2014). Alignment
of the β-jellyroll folds of LptF, LptC, LptA, and LptD in a
C-terminal-to-N-terminal arrangement is thought to allow the
formation of a hydrophobic groove that spans the periplasm
and accommodates the acyl chains of the LPS molecules during
transport (Villa et al., 2013; Okuda et al., 2016; Sperandeo et al.,
2019). Inhibition of bridge formation, as a consequence of Lpt
protein depletion in conditional expression mutants or due to
mutations that interfere with protein–protein interactions at any
level in the system, results in cell growth arrest and blocking
of Lpt, with accumulation of newly synthesized LPS in the IM
and formation of membranous bodies in the periplasm (Wu
et al., 2006; Sperandeo et al., 2007, 2008; Ruiz et al., 2008).
Accumulated LPS molecules can be decorated at the periplasmic
side of the IM by the addition of colanic acid units (Majdalani
and Gottesman, 2005; Sperandeo et al., 2008, 2011). Overall,
the Lpt mechanism mediated by the Lpt machinery has been
compared to that of a PEZ candy dispenser, where a spring at
the base of the dispenser loads the candy into the tube and
pushes them up to the cap, which then opens to release them
to the customer (Okuda et al., 2016). Interestingly, when the Lpt
bridge is not properly assembled, LptA undergoes degradation,
suggesting that the steady-state level of LptA in the cell, together
with the appearance of colanic acid-modified LPS, are diagnostic
of Lpt defects (Sperandeo et al., 2011).
Due to its relevance in Gram-negative bacteria cell physiology,
LPS biogenesis can be considered a promising target for the
development of novel antibacterial molecules. Potent inhibitors
of the lipid A biosynthesis were identified in past studies and
are continuously in development (Simpson and Trent, 2019).
Moreover, two compounds targeting the MsbA-mediated IM
translocation process have been recently reported (Ho et al.,
2018; Zhang et al., 2018). However, the only inhibitor of
LPS biogenesis to have entered, so far, Phase III trials is
Murepavadin, a macrocyclic peptidomimetic selectively directed
against Pseudomonas aeruginosa LptD (Srinivas et al., 2010;
Lehman and Grabowicz, 2019). Unfortunately, the clinical
trials have been suspended recently due to nephrotoxicity
(Lehman and Grabowicz, 2019). Nevertheless, the identification
of Murepavadin highlights the Lpt machinery as a good target for
the discovery of molecules endowed with antibacterial activity.
Very recently, a screening strategy based on the yeast two-
hybrid (YTH) system has allowed the isolation of a compound,
IMB-881, that disrupts LptC–LptA interaction, exerting
bactericidal activity against E. coli and other Enterobacterial
species (Zhang et al., 2019).
Here we show the implementation of the Bacterial Adenylate
Cyclase Two-Hybrid (BACTH) system (Karimova et al., 1998),
based on the interaction-mediated reconstitution of the adenylate
cyclase activity in E. coli, to allow the detection of LptC–LptA
and LptA–LptA interactions in their native environment, the
periplasm. We successfully reconstituted both interactions and
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FIGURE 1 | The Lpt machinery and thanatin. (A) The lipopolysaccharide transport system in Escherichia coli consists of a seven-protein complex organized in an
inner membrane (IM) ABC transporter (LptB2FGC) and an outer membrane (OM) translocon (LptDE) connected by a periplasmic protein, LptA, that bridges the
membranes. LptA is anchored to the IM through its interaction with LptC. The number of LptA molecules forming the bridge is not known. For clarity, only two
molecules of LptA are depicted. (B) Structure of thanatin.
exploited this system to more thoroughly investigate the effect of
the antimicrobial peptide thanatin.
Thanatin is a 21-residue inducible cationic defense peptide
isolated from the hemipteran insect Podisus maculiventris,
that contains one disulfide bond and exhibits a broad range
of antibacterial and antifungal activity (Fehlbaum et al.,
1996) (Figure 1B).
Important new insights into thanatin’s mode of action
against Gram-negative bacteria have been provided by a recent
work showing that thanatin binds to E. coli LptA and LptD
in vivo and in vitro (Vetterli et al., 2018). Accordingly,
spontaneous thanatin-resistant mutants isolated in the same
work share a single point mutation in the lptA gene, strongly
indicating LptA as the major target of thanatin. Analysis
of the nuclear magnetic resonance (NMR) structure of the
LptA–thanatin complex reveals that the interaction occurs at
the N-terminal β-strand of the β-jellyroll of LptA, region
involved in LptA interaction with LptC and/or with another
monomer of LptA (Suits et al., 2008; Freinkman et al.,
2012). It has been thus speculated that thanatin might exert
its antibacterial activity by interfering with the interactions
established by LptA within the Lpt bridge (Vetterli et al.,
2018). However, no evidence supporting this hypothesis has
been published yet.
Our investigation provides more insights into thanatin’s
mode of action against Gram-negative bacteria showing that it
interferes with LptC–LptA interaction in vivo. Disruption of the
Lpt protein bridge is further supported by LptA degradation and
appearance of LPS modified by colanic acid in thanatin treated
cells. The results of this work strongly validate the assembly of
the Lpt machinery as a promising target for the development of a
novel class of antibacterial or adjuvant drugs.
MATERIALS AND METHODS
Bacterial Strains and Media
Escherichia coli strains and plasmids used in this study are listed
in Table 1. AM604 genomic DNA was used as template for
PCR and the XL1-Blue strain was used in all cloning steps.
The strain MG1655 was used in the study of LptA stability and
in the analysis of LPS profiles. BACTH assays were performed
with the E. coli 1cya strain BTH101 (Karimova et al., 1998;
Ouellette et al., 2017). The strains M15/pREP4 and BL21(DE3)
were used in the purification of LptC24−191 (Sperandeo et al.,
2011) and LptAm (Laguri et al., 2017), respectively. Bacteria
were grown in Luria–Bertani (LB) medium (10 g/L tryptone,
5 g/L yeast extract, 10 g/L NaCl) or LB-agar medium (LB
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medium with 10 g/L agar). When required, antibiotics or
inducer were added at the following concentrations: ampicillin
at 100 µg/mL, spectinomycin at 50 µg/mL, isopropyl-β-D-
thiogalactopyranoside (IPTG) at 0.5 mM.
Plasmid Construction
To construct the recombinant plasmids used in the BACTH
assay (listed in Table 1), the genes encoding the Lpt proteins
of interest (or their subdomains) were PCR-amplified using the
appropriate primer pairs, as listed in Table 2. The PCR products
were then digested with the indicated restriction enzymes
and subcloned into the corresponding sites of the pSTM25
and pUTM18C vectors. These BACTH vectors, expressing the
T25 and T18 fragments of the adenylate cyclase toxin of
Bordetella pertussis fused at their C-terminal ends with the
first transmembrane domain of the E. coli OppB protein
(TM), were employed in order to study protein interactions
in the periplasm (Ouellette et al., 2014). In the recombinant
plasmids pST25-LptC and pUT18C-LptC, full-length LptC
(comprising its own transmembrane domain) was fused at the
C-terminal end of the T25 and T18 fragments, respectively.
MalE, LptA, and LptAm were fused to the C-terminal end of
TM to originate the constructs pUTM18C-MalE, pSTM25-LptA,
pUTM18C-LptA, pSTM25-LptAm, and pUTM18C-LptAm. The
recombinant plasmids pSTM25-LptAQ62L, pUTM18C-LptAQ62L,
and pUTM18C-LptAmQ62L were constructed by using a Q5 site-
directed mutagenesis kit (New England Biolabs) with the primer
pair AP733-AP734. Transformation was performed in XL1-Blue
electrocompetent cells and transformants were selected at 30◦C
on LB plates supplemented with the appropriate antibiotics
(ampicillin or spectinomycin), and 0.4% glucose to repress
expression. All the cloned DNA regions obtained by PCR were
verified by sequencing.
Bacterial Adenylate Cyclase Two-Hybrid
(BACTH) Assay
To study protein–protein interactions with the BACTH system,
electrocompetent BTH101 cells were co-transformed with each
pair of plasmids to be tested (Figure 2A), plated onto LB
plates containing selective antibiotics (100 µg/mL ampicillin
and 50 µg/mL spectinomycin) and incubated at 30◦C for 24–
48 h. Interaction efficiencies were quantified by determining the
β-galactosidase activities in 96-well microtiter plates according
to a protocol adapted from Paschos et al. (2011). For
this measurement, at least eight clones from each plasmid
combination were analyzed for β-galactosidase activity in two
independent experiments. Each clone was inoculated in 1 mL
of LB medium supplemented with antibiotics and 0.5 mM
IPTG for overnight induction. The β-galactosidase activity was
measured from 20 µL culture diluted in 80 µL PM2 buffer
(70 mM Na2HPO4. 12H20, 30 mM NaH2PO4. H2O, 1 mM
MgSO4, 0.2 mM MnSO4, pH 7.0) containing 8 mg/mL ortho-
nitrophenyl-β-galactoside (ONPG), 0.01% SDS, and 50 mM β-
mercaptoethanol. Reaction mixtures were incubated at room
temperature for 20–30 min or until a sufficiently yellow color
had developed, and the reactions were stopped with 100 µL
1 M Na2CO3. The optical densities at 420 and 550 nm
were recorded for each sample using a plate reader (EnSpire
Multimode Plate Reader, PerkinElmer) and the specific activity
was calculated with the formula: Miller units = [OD420 -
(1.75 × OD550)]/[t × OD600 × (volume in mL)] × 1000, where
OD600 is the optical density at 600 nm after overnight incubation
and t is the time in minutes needed for color formation.
Peptide Synthesis
Peptides were synthesized on a 0.1 mmol scale on a Wang
resin 0.99 mmol/g. The first amino acid was attached to the
resin following a protocol described in the literature (Avitabile
et al., 2019). The peptides were then elongated on a Liberty Blue
CEM synthesizer using standard protocols. At the end of the
synthesis, the peptides were cleaved from the resin and protecting
groups were removed by treating the resin with a solution of
TFA/thioanisol/H2O 95/2.5/2.5 v/v/v for 2 h. The peptides were
then lyophilized. Wild type (WT) peptide was cyclized as reported
by Fehlbaum et al. (1996). Peptides were purified by RP-HPLC
on a Jupiter 10µ Proteo 90A◦ (100 × 21.20 mm) column using
a gradient of CH3CN (0.1% TFA) in H2O (0.1% TFA) from 10
to 50% in 20 min and analyzed on a Vydamass C18 100A 5µ
150 × 4.6 mm column with the same gradient. Peptides were
characterized by mass spectrometry on a Thermo Scientific LCQ
Fleet ion trap. Pure peptides were then lyophilized three times,
the first to eliminate HPLC solvents, the second from a solution
6/4 v/v H2O /CH3COOH, and the third in water.
Thanatin WT Cyclic
Sequence: GSKKPVPIIYCNRRTGKCQRM
Calculated mass (Da): 2433.95; found (Da): 1217.08
[M+2H]2+; 812.33 [M+3H]3+; 609.29 [M+4H]4+
Thanatin Scramble (Scr)
Sequence: YVCIRMNKISPKQRTPGGRCK
Calculated mass (Da): 2435.95; found (Da): 1219.02
[M+2H]2+; 813.47 [M+3H]3+; 610.50 [M+4H]4+
Determination of Minimal Inhibitory
Concentration (MIC)
The minimal inhibitory concentration (MIC) values of thanatin,
thanatin scramble, and vancomycin (as a positive control) were
assessed with a protocol adapted from Wiegand et al. (2008) using
96-well microtiter plates. Stationary phase cultures of the E. coli
WT strain MG1655 (Blattner et al., 1997), the permeabilized
mutants AS19 (Sekiguchi and Iida, 1967) and NR698 (Ruiz et al.,
2005), and the BACTH strain BTH101 (Karimova et al., 1998;
Ouellette et al., 2017) grown at 37◦C in LB medium, were diluted
in fresh medium adjusting the OD600 to a value of 0.05 and
incubated in the presence of twofold decreasing concentrations
of the compounds ranging from 64 µg/mL to 62.5 ng/mL. After
24 h of incubation at 37◦C, the OD600 was measured by a plate
reader (EnSpire Multimode Plate Reader, PerkinElmer). The MIC
value was determined as the lowest concentration of compound
leading to no detectable growth.
Frontiers in Microbiology | www.frontiersin.org 4 May 2020 | Volume 11 | Article 909
fmicb-11-00909 May 11, 2020 Time: 19:25 # 5
Moura et al. Thanatin Impairs Lpt Complex Assembly
TABLE 1 | Escherichia coli strains and plasmids.
Strain or plasmid Relevant genotype or description Source or references
Strains
MG1655 K-12, F− λ− ilvG− rfb-50 rph-1 Blattner et al., 1997
AM604 MC4100 ara + Wu et al., 2006
AS19 E. coli strain B, hyperpermeable strain Sekiguchi and Iida, 1967
NR698 imp4213 Ruiz et al., 2005
XL1-Blue recA1 endA1 gyrA96 (NalR) thi-1 hsdR17 supE44 relA1 lac
[F’ proAB lacIqZ1M15 Tn10 (TetR)]
NEB
BTH101 F− cya-99 araD139 galE15 galK16 rpsL1 (StrR) hsdR2
mcrA1 mcrB1
Karimova et al., 1998; Ouellette et al., 2017
M15/pREP4 F− lac thi mtl/pREP4 QIAGEN
BL21(DE3) F− ompT gal dcm lon hsdSB(rB− mB−) (λDE3 [lacI
lacUV5-T7 gene 1 ind1 Sam7 nin5])
Studier and Moffatt, 1986
Plasmids ori
pSTM25 aadA Plac::t25-TM p15A Ouellette et al., 2014
pUTM18C bla Plac::t18-TM ColE1 Ouellette et al., 2014
pUTM18C-MalE malE sequence (residues 27–396) cloned downstream
T18-TM
ColE1 This study
pSTM25-LptAm lptA sequence (residues 28–159) cloned downstream
T25-TM
p15A This study
pUTM18C-LptAm lptA sequence (residues 28–159) cloned downstream
T18-TM
ColE1 This study
pUTM18C-LptAmQ62L lptA sequence (residues 28–159) bearing a Q-to-L mutation
at position 62 cloned downstream T18-TM
ColE1 This study
pSTM25-LptA lptA sequence (residues 28–185) cloned downstream
T25-TM
p15A This study
pSTM25-LptAQ62L lptA sequence (residues 28–185) bearing a Q-to-L mutation
at position 62 cloned downstream T25-TM
p15A This study
pUTM18C-LptA lptA sequence (residues 28–185) cloned downstream
T18-TM
ColE1 This study
pUTM18C-LptAQ62L lptA sequence (residues 28–185) bearing a Q-to-L mutation
at position 62 cloned downstream T18-TM
ColE1 This study
pST25-LptC lptC full-length sequence cloned downstream T25 p15A This study
pUT18C-LptC lptC full-length sequence cloned downstream T18 ColE1 This study
pQEsH-lptC pQE30 (QIAGEN) derivative, expresses His6-LptC24−191;
bla
Sperandeo et al., 2011
pET-LptA1160−185 –H pT7-lptA1160−185 -His6; bla Laguri et al., 2017
TABLE 2 | Oligonucleotides.
Name Sequence (5′–3′)a Used to make
AP576 Reverse attgtggatccTTAAGGCTGAGTTTGTTTG lptC cloning in pSTM25 and pUTM18C; BamHI
AP579 Forward taatgtcgacgAAAATCGAAGAAGGTAAACTG malE cloning in pUTM18C; SalI
AP580 Reverse aaggatctagaTTACTTGGTGATACGAGTCTGC malE cloning in pUTM18C; XbaI
AP581 Forward gagacgagctcgGTAACCGGAGACACTGATCAG lptA and lptAm cloning in pUTM18C; SacI
AP582 Reverse gagaggaattcTTAATTACCCTTCTTCTGTGC lptA cloning in pUTM18C; EcoRI
AP665 Reverse gagaggaattcTTAGCGCTTGCCTTTGTCG lptAm cloning in pUTM18C; EcoRI
AP666 Forward aaggatctagagGTAACCGGAGACACTGATCAG lptA cloning in pSTM25; XbaI
AP667 Reverse attgtggatccTTAATTACCCTTCTTCTGTGC lptA cloning in pSTM25; BamHI
AP688 Reverse attgtggatccTTAGCGCTTGCCTTTGTCG lptAm cloning in pSTM25; BamHI
AP689 Forward gaagatctgcagggATGAGTAAAGCCAGACGTTG lptC cloning in pSTM25; PstI
AP690 Forward gaagatctgcaggATGAGTAAAGCCAGACGTTG lptC cloning in pUTM18C; PstI
AP733 Forward ATCGTCACCCTGGGCACCATC Q62L mutagenesis in lptA
AP734 Reverse GACATTACCGGTAAAGGTAACC Q62L mutagenesis in lptA
aE. coli genomic sequence in uppercase; restriction sites in underlined lowercase; codon mutated by site-directed mutagenesis in bold.
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FIGURE 2 | BACTH analysis of interactions between the tested combinations. (A) List of constructs co-expressed in the BTH101 strain for BACTH analysis.
(B) β-Galactosidase activities are the results of at least two independent experiments in cells grown overnight in selective medium supplemented with IPTG. All
values were normalized by the average activity obtained for T25LptC–TM18LptAm (CAm) interaction. Each bar represents the mean value with standard deviation.
(C) Schematic representation of the interactions T25LptC–TM18LptAm (CAm) and TM25LptA–TM18LptA (AA). Full length LptC and truncated LptA were cloned in
frame to the T25 and T18 fragments, respectively (left diagram). Full length LptA was fused in frame to both adenylate cyclase fragments (right diagram). TM
indicates the transmembrane domain of OppB from E. coli. Peri, periplasm; IM, inner membrane; Cyt, cytoplasm.
Analysis of Thanatin’s Effect on Lpt
Protein Interactions Using the BACTH
Assay
To assess thanatin’s effect on the periplasmic interactions
LptA–LptA and LptC–LptAm, at least four clones from each
combination were cultured in LB medium supplemented with
antibiotics at 37◦C to an OD600 around 1.0. These precultures
were used to inoculate 1 mL of LB medium supplemented
with antibiotics, 0.5 mM IPTG, and thanatin at different
concentrations to an OD600 of 0.05; and the cultures were
incubated for 18 h (overnight) at 30◦C. After overnight induction
of the expression of the hybrid proteins, the β-galactosidase
activities were determined. For the clones expressing the BACTH
combination T25LptC-TM18LptAm, thanatin was tested at 0.7,
1.0, and 1.4 µg/mL. For the TM25LptA–TM18LptA pair, a
higher concentration of thanatin could be added to the cultures
without affecting bacterial growth; thus, values of 0.7, 1.0, 1.4,
and 2.8 µg/mL were tested. A scrambled version of thanatin (Scr)
was also employed in this assay at the same concentrations as a
control for the specificity of interaction inhibition.
Protein Production and Purification
Escherichia coli LptC lacking the first 23 residues of the
transmembrane domain was expressed from a plasmid (LptC
pQESH, QIAGEN) with an N-terminal His-Tag and purified
as described (Laguri et al., 2017). LptC was expressed in 15N
enriched deuterated medium with specific 13C-1H labeling of
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Isoleucines δ1 and Leucine and Valine proR methyl groups
according to standard protocols (Kerfah et al., 2015) with
NMRbio precursors1. LptAm coding for residues 28–159 followed
by a SGRVEHHHHHH TAG in a pET21b vector was expressed
and purified as described (Laguri et al., 2017). Both proteins were
exchanged to 50 mM Na2HPO4 pH 8.0, 150 mM NaCl buffer.
NMR Spectroscopy
Nuclear magnetic resonance experiments were recorded at
25◦C on Bruker 600 MHz spectrometer equipped with a
triple resonance cryoprobe. 2D-[1H, 13C]-methyl-SOFAST
experiments were recorded to follow LptC methyl groups on
LptC 15N2H and 13C-1H specifically labeled on Iδ1, Lδ1, and Vγ1
at 20 µM prepared in 50 mM Na2HPO4 pH 8.0, 150 mM NaCl
buffer with 10% D2O. Unlabeled LptAm at 40 µM prepared in
the exact same buffer was added to LptC to achieve 100% of LptC
complexed with LptAm. Thanatin or Scr at 42 µM was added to
the complex and interaction experiments were followed using
2D-[1H, 13C]-methyl-SOFAST experiments. NMR experiments
were processed and analyzed using Topspin 3.2 and CcpNmr 2.4.
Biacore Experiments
Surface plasmon resonance (SPR) experiments were performed
on a Biacore T200 with a CM3 chip. HBS-P+ and HBS-
N buffers (GE Healthcare) were used for immobilization and
interactions, respectively. 66 Resonance units (RUs) of LptAm
were immobilized on a flow cell by the amine (EDC-NHS)
coupling method followed by ethanolamine saturation, with
a flow cell modified only with EDC-NHS-ethanolamine as
reference for subtractions. For interactions, protein and ligands
were diluted in HBS-N running buffer and regeneration between
injections achieved with a 30 s pulse of 10 mM HCl. Sensorgrams
shown were subtracted with the reference flow cell as well as with
injection of buffer alone. Determination of LptC–LptAm Kd was
performed by injecting increasing concentrations of LptC (5.6–
100 µM) over immobilized LptAm. Kinetics analysis of the data
was unsuccessful due to very fast association, and the Kd was
determined from steady-state binding levels obtained at the end
of the association phase with Bioeval software (GE Healthcare).
Determination of LptA, LptD, and LptB
Steady-State Levels Upon Thanatin
Treatment
LptA, LptD, and LptB (as loading control) steady-state levels
were assessed in the MG1655 strain by western blot analysis
with polyclonal antibodies raised in rabbit against LptA, LptD,
and LptB. Bacterial cultures were grown at 37◦C in LB medium.
At OD600 0.1, the cells were treated or not with 5.25 µg/mL of
thanatin (1.5 ×MIC). Cell growth was monitored by measuring
the OD600 value at 30-min intervals and viability was determined
by quantifying the colony-forming units (CFU) at 1-h intervals
during a time period of 4 h. Whole-cell extracts for protein
analysis were collected and harvested by centrifugation (5000 g,
10 min) 20, 30, 40, 60, and 120 min after treatment with thanatin.
1http://www.nmr-bio.com/
The cell pellets were resuspended in a volume (in mL) of SDS
Laemmli buffer equal to 1/24 of the total optical density of the
sample. The samples were boiled for 5 min and equal volumes
(15 µL) were separated by 12.5% SDS-PAGE. Proteins were
transferred onto nitrocellulose membranes (GE Healthcare),
and immunodecoration was performed as previously described
(Sperandeo et al., 2007). Polyclonal antibodies raised against
LptA (GenScript Corporation), LptD (GenScript Corporation),
and LptB (kindly provided by D. Kahne and N. Ruiz) were
used as primary antibodies at dilutions of 1:1,000, 1:500, and
1:10,000, respectively. As secondary antibody, goat anti-rabbit
immunoglobulin (Li-Cor) was used at a dilution of 1:15,000.
Bands were visualized by an Odyssey Fc imaging system (Li-
Cor GmbH).
LPS Analysis From Whole-Cell Extracts
Whole-cell extract samples for LPS analysis were obtained as
described in the previous section. For LPS visualization, equal
volumes (20 µL) of whole-cell extracts were digested with
6 µg of proteinase K (Sigma–Aldrich) at 60◦C for 1 h and
then separated by 18% Tricine SDS-PAGE (Lesse et al., 1990).
Immunodecoration was performed using anti-LPS core WN1
222-5 monoclonal antibodies (Hycult Biotech) at a dilution of
1:500. As secondary antibody, goat anti-mouse immunoglobulin
G-peroxidase (HRP) conjugate (Sigma–Aldrich) was used at a
dilution of 1:5000.
RESULTS
Adaptation of the BACTH Assay for the
Detection of Lpt Protein Interactions in
the Periplasm
The BACTH system was implemented in this work to allow
the detection in vivo of two crucial protein-protein interactions
within the Lpt interactome, namely, LptC–LptA and LptA–
LptA. The BACTH assay is based on the interaction-mediated
reconstitution of the adenylate cyclase activity of the toxin of
B. pertussis, whose catalytic domain can be divided in two
complementary fragments, T25 and T18 (Karimova et al., 1998;
Battesti and Bouveret, 2012). In this work, we used the BACTH
vectors expressing these fragments fused in frame with the
first transmembrane domain of the E. coli OppB protein (TM)
(pSTM25 and pUTM18C). These plasmids allow expression of
the targeted protein domains fused to TM25 and TM18 into the
periplasm (Ouellette et al., 2014) which reflects the physiological
environment of the tested interactions. To detect LptA–LptA
dimerization, LptA was subcloned into both BACTH vectors at
the C-terminal end of the TM, originating the hybrid TM25LptA
and TM18LptA proteins. To detect LptC–LptA association, we
fused at the C-terminal end of the TM a truncated monomeric
version of LptA, referred to as LptAm, that lacks the last
C-terminal β-strand and is not able to self-oligomerize, although
still functional in vivo (Laguri et al., 2017). We decided to
use LptAm to avoid titration of the fusion protein caused by
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interaction of LptA with itself, leading to a decrease in the β-
galactosidase signal when testing LptC–LptA interaction with the
BACTH technique. Full-length LptC was subcloned into both
pSTM25 and pUTM18C vectors, in frame with the C-terminal
end of the adenylate cyclase fragments, to obtain the constructs
T25LptC and T18LptC.
As negative controls for the assay, we used: (i) the combination
between the void plasmids pSTM25 and pUTM18C; (ii) the non-
productive LptAm–LptAm association; and (iii) the association
LptC–MalE, between LptC and the unrelated periplasmic binding
subunit of the E. coli maltose transporter, MalE (Davidson et al.,
1992; Ehrmann et al., 1998). Constructs were transformed into
the adenylate cyclase-deficient strain BTH101 and the efficiency
of interaction between the various protein fusions was quantified
by measuring the β-galactosidase activity. The results for the
BACTH complementation assay are presented in Figures 2A,B.
As expected, LptC–MalE combination did not produce a positive
interaction signal, confirming that the BACTH system is suitable
to detect specific interactions occurring in the periplasm. Also,
truncated LptA was confirmed to be unable to oligomerize. We
successfully detected in vivo the LptC–LptAm interaction and the
dimerization of LptA (schematic representation in Figure 2C).
The signal obtained for the pair T25LptC–TM18LptAm (CAm)
was twofold higher than the one obtained for the complementary
combination TM25LptAm–T18LptC (AmC). This effect is not
surprising since it was previously reported that β-galactosidase
measurements may significantly vary according to the T25 and
T18 combination chosen for the BACTH assay (Ouellette et al.,
2017). Indeed, when testing the LptC–LptAm interaction, hybrid
LptAm can be titrated away from the reaction by interaction
through its N-terminal with native LptA. This effect is likely even
more significant in the TM25LptAm–T18LptC configuration,
where LptAm is expressed from a low-copy number vector
(pSTM25), thus further diminishing the number of hybrid LptAm
proteins free to interact with LptC and accounting for the lower
β-galactosidase signal observed in AmC combination. Therefore,
we decided to use the pair of constructs T25LptC–TM18LptAm in
further tests. It should be noted that in our assay, the interaction
of full-length LptA with itself (LptA–LptA) produced a lower
β-galactosidase activity signal compared to LptC–LptAm. This
is consistent with previously published in vitro measurements
revealing that the affinity between LptA and LptC is stronger than
the affinity for LptA oligomerization (Schultz et al., 2013).
Thanatin Inhibits LptC–LptAm and
LptA–LptA Interactions in vivo
Interaction between the antibacterial peptide thanatin and LptA
was recently demonstrated and NMR experiments clearly showed
that the N-terminal strand of the β-hairpin of thanatin docks
in parallel orientation onto the first N-terminal β-strand of
the β-jellyroll of LptA (Vetterli et al., 2018). It is well known
from structural studies that dimerization of LptA monomers
with themselves or with LptC involves the N-terminal edge
strand of the β-jellyroll of LptA (Suits et al., 2008; Schultz
et al., 2013; Laguri et al., 2017). Thanatin’s binding site therefore
overlaps with the interaction site of LptA with another LptA
FIGURE 3 | Thanatin’s effect on LptA–LptA (AA) and LptAQ62L–LptAQ62L
(A*A*) interactions. Thanatin and thanatin scramble (Scr) were tested at
concentrations ranging from 0.7 to 2.8 µg/mL. All values were normalized by
the average activity obtained for the untreated LptA–LptA interaction. Values
are averages of at least eight technical replicates from two independent
experiments ± standard deviation.
subunit in the homodimer LptA–LptA and with LptC in the
heterodimer LptA–LptC, suggesting a possible mechanism for
the antibacterial activity. We thus analyzed the effect of thanatin
on these interactions with the adapted BACTH assay and used
a scrambled version of thanatin, characterized by the same
amino acid composition but with a different sequence (thanatin
scramble, Scr), as specificity control (Figures 3, 4). The MIC
of thanatin and thanatin scramble was assessed against WT
MG1655, and permeabilized AS19 and NR698 E. coli strains.
The MIC values were 1.8–3.5 and above 64 µg/mL for thanatin
and thanatin scramble, respectively, when tested against the
WT MG1655 strain (Table 3). Slightly lower MIC values were
obtained for thanatin when tested against the permeabilized
E. coli mutants (0.1–0.4 µg/mL). On the contrary, no significant
difference relative to the WT strain was observed in the MIC
values of thanatin scramble when tested against the permeabilized
mutant strains, suggesting that the lower activity of the peptide
cannot be attributed to its inability to cross the OM barrier.
To explore whether thanatin’s antibacterial activity is due
to the inhibition of LptA interaction with itself or with LptC,
we evaluated the effect of increasing sub-MIC concentrations
of the peptide on the TM25LptA–TM18LptA and T25LptC–
TM18LptAm associations and the results are presented in
Figures 3, 4, respectively. After overnight induction of the fusion
proteins in the presence of thanatin, we could observe inhibition
not only of LptA–LptA dimerization but also of LptC–LptAm
interaction, but the inhibitory effect was much greater on the
latter. A clear dose-dependent response could only be observed in
the inhibition of LptC–LptAm interaction. The thanatin scramble
was not capable of disrupting these periplasmic interactions in a
dose-dependent manner, indicating that this is an effect specific
to thanatin secondary and tertiary structures rather than to any
cationic peptide with the same amino acid composition.
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FIGURE 4 | Thanatin’s effect on LptC–LptAm (CA) and LptC–LptAmQ62L (CA*)
interactions. Thanatin and thanatin scramble (Scr) were tested at
concentrations ranging from 0.7 to 1.4 µg/mL. All values were normalized by
the average activity obtained for the untreated interaction LptC–LptAm. Values
are averages of at least eight technical replicates from two independent
experiments ± standard deviation.
TABLE 3 | Minimal inhibitory concentrations (MICs) in µg/mL of thanatin, thanatin
scramble, and vancomycin.
MIC (µg/mL)
Strains Thanatin Thanatin scramble Vancomycin
MG1655 1.8–3.5 >64 >64
AS19 0.1–0.2 64 4.0–8.0
NR698 0.1–0.4 32–64 0.5–1.0
BTH101 3.5 >64 >64
Compounds were tested against wild-type (MG1655) and permeable (AS19 and
NR698) Escherichia coli strains. The BTH101 strain used in the BACTH assay was
also tested. The data are representative of three biological replicates.
We also tested a previously isolated thanatin-resistant mutant
presenting a glutamine to leucine substitution at position 62 in
the LptA protein (lptAQ62L allele) (Vetterli et al., 2018). The
lptA-Q62L mutation was introduced into the BACTH constructs
and tested as described above (Figures 3, 4). The data obtained
suggest that Q62L mutation in LptA specifically impairs the
ability of thanatin to disrupt LptC–LptAmQ62L (CA∗) association,
since the peptide is not effective against CA∗ at concentrations
at which it is active against the WT CA pair, namely, 0.7 and
1µg/mL (Figure 4). It should be noted that Q62L mutation exerts
an unexpected stabilizing effect on LptAQ62L–LptAQ62L (A∗A∗)
interaction, resulting in a β-galactosidase signal higher than that
of the WT LptA–LptA combination. This effect is abolished
upon treatment with thanatin, although not in a dose-dependent
manner (Figure 3). Residue Q62 is not directly involved in the
interaction of LptA with another LptA monomer, LptC, or with
thanatin but belongs to a loop of the β-jellyroll of LptA that
comes into contact with the short N-terminal α-helix of the WT
protein upon thanatin interaction (Vetterli et al., 2018). This
effect could be explained assuming that Q62L mutation induces a
conformational change in the N-terminal region of LptA, which
alters the way all these three interactions occur. Since thanatin’s
binding site overlaps the binding site of LptA with another LptA
protein, if the Q62L mutation somehow alters thanatin’s binding,
then it is possible that it also alters the interaction of LptAQ62L
with itself, perhaps by strengthening it.
A similar stabilizing effect is also observed when testing the
LptC–LptAmQ62L combination. However, in this case, the effect
is observed only upon treatment with low concentrations of
thanatin, since the β-galactosidase signal of non-treated CA∗
is comparable to that of the WT (Figure 4). This suggests
that LptAmQ62L is still able to bind thanatin and this binding
determines a conformational change in the protein that somehow
enhances the stability of LptC–LptAmQ62L complex. At higher
thanatin concentrations, however, it seems that the inhibitory
effect of the peptide on LptC–LptAmQ62L prevails over the
stabilizing effect. This could be explained by hypothesizing
that Q62L mutation in LptA creates a secondary high-affinity
binding site for thanatin. According to this hypothesis, when
low concentrations of thanatin are added, thanatin binds to the
high-affinity site, leaving the binding site for LptC unoccupied
(and possibly stabilizing LptC–LptAmQ62L complex). On the
contrary, when higher concentrations of thanatin are used, all the
available binding sites are occupied, thus impairing LptC–LptA
complex formation.
Thanatin Disrupts LptC–LptAm
Interaction in vitro
Thanatin’s ability to interfere with LptC–LptA complex
formation was assessed by NMR and SPR. For these assays, the
monomeric version of LptA (LptAm) was used to neglect the
oligomerization of LptA. 1H-13C NMR of the specifically labeled
Isoleucines of LptC efficiently report on the interaction with
LptA (Laguri et al., 2017). In particular, Isoleucines 175 (175Ile)
and 184 (184Ile) δ1 methyl groups at the C-terminus of LptC
and in the vicinity of the binding interface change chemical
shifts upon formation of the complex with LptAm (Figure 5A,
left panel). After adding thanatin to the LptC–LptAm complex,
we observed that 175Ile and 184Ile peaks completely shifted
to a frequency corresponding to free LptC, indicating a total
disruption of LptC–LptAm dimers (Figure 5A, right panel). The
same experiment performed with the thanatin scramble (Scr)
showed no disruption of the LptC–LptAm complex, suggesting
specific competition and disruption of the binding interface by
the thanatin (Figure 5A, right panel).
Complex disruption was also probed by SPR, in which the
surface of a chip was functionalized with LptAm. First, we
confirmed the binding of LptC to the immobilized LptAm
(Supplementary Figure S1A) and we determined the Kd of
the interaction (Kd = 80 ± 44 µM). Then, to assess thanatin’s
effect, we injected thanatin over LptAm and confirmed stable
interaction with LptAm on the surface, followed by the injection
of LptC (Figure 5B, upper panels). We observed that, upon LptC
injection, the response values decreased in a dose-dependent
manner to the thanatin injected in the system (in concentrations
up to 1 µM), indicating fewer surface-free LptAm epitopes
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FIGURE 5 | LptC–LptA interaction is specifically disrupted by thanatin. (A) [1H, 13C]-correlation spectra of methyl labeled LptC in absence (black) and presence (red)
of two molar equivalents of LptAm, focused on Isoleucines in black for signals corresponding to isolated LptC and in red for LptC in complex with LptAm (left panel).
A 1D-13C projection of the 2D experiment is shown on the side for clarity. On the right panel, addition of thanatin disrupts LptC–LptAm interaction originating signals
characteristic of LptC alone (black). Thanatin scramble (Scr) did not change LptC–LptAm spectra, indicating intact LptC–LptAm complexes (red). (B) Monitoring of
LptC–LptAm interaction upon thanatin treatment by SPR. (Left panels) Thanatin or Scr were injected over surface-immobilized LptAm, with concentrations following a
color-code in bold: 0 (black), 0.1 µM (yellow), or 1 µM (red). Thanatin interacts strongly with LptAm presenting rapid association and slow dissociation. (Right panels)
For clarity, after previous injections with the same concentrations of thanatin/Scr, sensorgrams were readjusted to 0, followed by LptC injection at 10 µM and
recording. Binding of LptC to immobilized LptAm is reduced with increasing thanatin concentrations previously flowed (maximum at 1 µM), while Scr displays no
effect.
available to interact with LptC (Figure 5B, upper right panel).
The same experiment with the scrambled version showed no or
little binding of Scr to immobilized LptAm and hence no effect on
LptC binding (Figure 5B, lower panels), further demonstrating a
specific effect of thanatin in preventing the formation of LptC–
LptAm complex.
Thanatin Treatment Results in LptA
Degradation and LPS Modification
Depletion of components of the IM and OM Lpt sub-complexes
results in LptA degradation, which has been proposed to be a
marker of incorrect complex assembly (Sperandeo et al., 2011).
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We reasoned that the disruption of LptC–LptA interaction
by thanatin treatment could impair Lpt complex assembly.
Therefore, we evaluated the LptA steady-state levels in E. coli
WT cells upon treatment with thanatin. Samples were taken at
different time points within 2 h from MG1655 cultures grown in
the presence or absence of thanatin at 5.25 µg/mL (1.5 × MIC)
and analyzed by western blotting using anti-LptA antibodies. The
abundance of LptD, the OM docking element of LptA, was also
assessed and the level of LptB was used as a sample loading
control. Culture growth and cell viability were monitored by
OD600 measurement and determination of CFU, respectively,
for a time span of 4 h. In cultures treated with thanatin, we
observed a decrease in the OD600 with minor effect on cell
viability (Figure 6A). As shown in Figure 6B, substantial LptA
degradation occurs within 60 min of incubation with thanatin
and, after 120 min, the steady-state level of LptA is very low
and almost undetectable with our antibody preparation. The
abundance of LptD did not change over time, indicating that
the steady-state level of this OM component is not affected
by thanatin treatment. The decrease in LptA level suggests
that the IM and OM are not properly bridged when cells are
treated with thanatin.
Depletion of any Lpt component leads to the accumulation
of LPS decorated with colanic acid repeating units at the
IM outer leaflet (Ruiz et al., 2008; Sperandeo et al., 2008).
This phenotype is diagnostic of defects in Lpt occurring
after MsbA-mediated flipping of lipid A-core across the IM.
We therefore tested whether treatment with thanatin would
induce similar LPS modifications. As shown in Figure 6C, LPS
decorated with colanic acid, migrating as ladder-like bands in
gel electrophoresis, was detected 120 min after adding thanatin
to the culture; no LPS modification was observed in untreated
cells. These data suggest that thanatin, by disrupting the LptC–
LptA interaction, impairs Lpt complex assembly leading to
the accumulation of LPS at the periplasmic side of the IM,
where it is decorated with colanic acid. The observed LPS
profile, together with the LptA degradation kinetic, strongly
suggests that the disruption of the Lpt protein bridge could
be the major killing mechanism of thanatin against Gram-
negative bacteria.
DISCUSSION
The LPS export pathway is a valuable target for novel antibiotic
discovery. Murepavadin, a macrocyclic peptidomimetic, has thus
far been the most promising antibiotic candidate targeting
the Lpt machinery. It was originally identified from a library
of structural mimics of class I CAMP (cationic antimicrobial
peptide) protegrin and later found to target the β-barrel OM
protein LptD (Srinivas et al., 2010; Werneburg et al., 2012;
Andolina et al., 2018).
Recent efforts to target the Lpt pathway have led to
the identification, through a YTH assay, of IMB-881 as a
synthetic molecule inhibiting LptC–LptA interaction (Zhang
et al., 2019). The inhibitory activity of IMB-881 further suggests
that interfering with the Lpt interactome is a good strategy
to prevent Lpt to the cell surface. Nevertheless, in the YTH
system, LptC–LptA interaction occurs in the cytoplasm of a
yeast cell, and molecules active in this system may not be
able to permeate the bacterial OM. To improve the screening
system, we here implemented the BACTH assay (Karimova et al.,
1998; Ouellette et al., 2014, 2017) that enables targeting of
Lpt protein interactions in their native environment, preserving
both protein functionality and folding state. This bacterial two-
hybrid technique was used to probe LpC–LptA and LptA–LptA
interactions. LptC has an important structural role in the Lpt
machinery as it serves as the docking site for LptA binding to the
IM LptB2FGC complex (Sperandeo et al., 2011; Freinkman et al.,
2012). Indeed, mutations in LptC compromising interaction with
LptA are lethal (Sperandeo et al., 2011; Villa et al., 2013). LptA
molecules have a strong tendency to oligomerize in solution
(Suits et al., 2008; Merten et al., 2012; Santambrogio et al., 2013)
but we still do not know whether LptA self-oligomerization has
a physiological relevance, since a monomeric LptA is still able to
partially support cell growth (Laguri et al., 2017). In the BACTH
assay, LptC–LptA interaction appears stronger than LptA–LptA
dimerization, in line with the reported in vitro affinities (Schultz
et al., 2013); however, we cannot exclude that the observed lower
β-galactosidase signal could also be due to the formation of
non-productive interactions between LptA molecules fused to
the same (T25 or T18) adenylate cyclase fragment. The assay
seems robust as no association is detected between unrelated non-
interacting proteins: LptC and the maltose periplasmic binding
protein MalE (Davidson et al., 1992) or between oligomerization
deficient LptAm proteins (Laguri et al., 2017).
The BACTH system was also employed to explore the
mechanism of action of thanatin, an antimicrobial peptide
recently shown to bind the first β-strand of LptA (Vetterli
et al., 2018). Thanatin inhibits LptC–LptA interaction in a dose-
dependent manner, whereas very little and non-dose dependent
inhibitory effect is observed against LptA–LptA association. LptA
first N-terminal β-strand is a key determinant interacting with the
C-terminal region of LptC or the C-terminal region of another
LptA in head-to-tail LptA self-oligomerization (Freinkman et al.,
2012; Laguri et al., 2017). LptC and LptA share a very similar
protein architecture, despite no amino acid sequence similarity
(Tran et al., 2010; Villa et al., 2013); indeed, in the LptC–LptAm
complex, LptC precisely occupies the same position as LptA in
the LptA oligomer (Laguri et al., 2017). Interestingly, thanatin
seems able to discriminate between the two different interactions
that LptA is implicated on via its N-terminal region and could,
therefore, also serve as a tool to probe the different interactions
occurring within the Lpt periplasmic protein bridge. This result
is in agreement with earlier data showing that the enantiomeric
form of thanatin (D-thanatin) is nearly inactive against Gram-
negative strains, suggesting that a stereospecific recognition by
a cellular target is required for thanatin to exert its antibacterial
effect (Fehlbaum et al., 1996).
A scrambled version of thanatin, that maintains the
overall peptide amino acid composition and charge, loses the
antibacterial activity, fails to disrupt the LptC–LptA interaction
in vivo (BACTH assay) and in vitro (NMR), and does not bind
to LptAm (SPR analyses). These data further support a specific
action of thanatin in binding to LptA and in competing with LptC
for the formation of the LptC–LptA complex. Thanatin scramble
Frontiers in Microbiology | www.frontiersin.org 11 May 2020 | Volume 11 | Article 909
fmicb-11-00909 May 11, 2020 Time: 19:25 # 12
Moura et al. Thanatin Impairs Lpt Complex Assembly
FIGURE 6 | LptA steady-state level and LPS profile upon treatment with thanatin. (A) Growth curves of wild type strain MG1655 in the presence (+ Than) and
absence (no Than) of thanatin at 5.25 µg/mL (1.5 × MIC) concentration. Growth was monitored by measuring the OD600 (left panel) and by determining CFU/mL
(right panel). (B) Western blot analysis to reveal LptA steady-state levels. Samples were collected 20, 30, 40, 60, and 120 min after treatment with thanatin.
Whole-cell extracts were prepared and analyzed by western blot with anti-LptA, anti-LptD, anti-LptB (as loading control) antibodies. An equal amount of cells (0.36
OD600 units) was loaded into each lane. (C) Western blot analysis to reveal LPS profiles. Whole-cell extracts obtained 30, 40, 60, and 120 min after treatment with
thanatin were incubated with proteinase K and analyzed by western blot with anti-LPS antibodies. An equal amount of cells (0.48 OD600) was loaded into each lane.
Results shown are representative of three independent experiments.
does not display antibacterial activity against permeabilized
E. coli strains, strongly suggesting that the lack of activity of the
scrambled peptide is not due to its inability to reach its target
in the periplasm.
It has been reported that E. coli cells carrying LptAQ62L
amino acid substitution become resistant to thanatin (Vetterli
et al., 2018). Residue Q62 does not appear to be implicated
in thanatin binding and the mechanism underlying resistance
is still unknown. LptC–LptAQ62L interaction is not inhibited
by thanatin in the BACTH assay and, surprisingly, it appears
stronger in the presence of the peptide. In the case of the
interaction between LptAQ62L mutant proteins, the dimerization
seems stronger than that observed between WT LptA, even in
the absence of thanatin. We can speculate that Q62L mutation
somehow alters the stability of both LptC–LptA and LptA–LptA
complexes, affecting the binding of thanatin to LptA. However,
it is difficult to explain these results since neither the effect of
the Q62L substitution on LptA structure nor the mechanism of
thanatin resistance are known.
Previous in vitro data revealed that besides LptA, thanatin
binds to the LptDE complex in the low nanomolar range
and, furthermore, its binding site in LptA has been shown by
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modeling studies to be highly conserved in the periplasmic
domain of LptD (Robinson, 2019). This suggests that thanatin
can inhibit multiple protein–protein interactions required for the
Lpt complex assembly. It was not possible to test the periplasmic
domain of LptD in the BACTH assay, since expression of a folded
and functional LptD is strictly dependent on the expression
and interaction with LptE (Chng et al., 2010). Nevertheless, the
isolation of suppressor mutants exclusively at the N-terminal
region of LptA (Vetterli et al., 2018), that is not involved in
the LptA–LptD interaction, and the ability of the LptAm mutant
protein, lacking the C-terminal β-strand implicated in both
LptA–LptA and LptA–LptD interactions, to partially support
the cell growth (Laguri et al., 2017) suggest that LptC–LptA
interaction is thanatin’s main target.
Thanatin has been related to the group of CAMPs that kill
bacteria by cell agglutination. In the host organism, this class
of antimicrobial peptides does not permeabilize bacterial cell
membranes but rather interacts with LPS or peptidoglycan,
favoring cell aggregation and bacterial removal by phagocytosis
(Shai, 2002; Jung et al., 2012; Pulido et al., 2012). Thanatin
has indeed been shown to bind LPS in vitro and promote cell
agglutination as a result of cell surface charge neutralization
(Sinha et al., 2017). Recently, the comparison of thanatin’s
affinity to LPS relative to Ca2+ and Mg2+ revealed that thanatin
displaces divalent cations from LPS in vivo promoting LPS
shedding from bacterial cells at concentrations 10-fold higher
than the MIC, increasing OM permeability (Ma et al., 2019).
Interestingly, the same study reports that thanatin is able to
inhibit the enzymatic activity of New Delhi metallo-β-lactamase-
1 (NMD-1), responsible for the resistance to β-lactam antibiotics
in several multidrug resistant strains, by binding to the active
site of the enzyme with higher affinity than Zn2+, displacing
it and reversing carbapenem resistance. This evidences that,
alongside a killing effect on Gram-negative pathogens based
on OM permeabilization, thanatin may help restoring the
activity of β-lactam antibiotics in multidrug resistant pathogens
(Ma et al., 2019).
In the reported BACTH assay, inhibition of LptC–LptA
interaction is observed at sub-MIC concentrations of thanatin,
a condition that does not inhibit the growth of cells expressing
LptC and LptAm protein fusions. Based on our data, we propose
that LPS binding is employed by thanatin as a self-promoted
mechanism of entry in the periplasm of bacterial cells where the
LptA target resides. Supporting this hypothesis is the finding of
a mutated version of thanatin, where Arg 13 and Arg 14 residues
have been substituted by Ala, that presents reduced LPS binding
affinity and loses the antibacterial activity (Sinha et al., 2017).
In E. coli cells treated with thanatin, LptA undergoes
degradation and LPS is decorated with colanic acid. Notably,
these phenotypes are observed in cells where LPS export
machinery disassembles and transport of LPS molecules is
impaired due to mutations in any of the Lpt complex components
(Sperandeo et al., 2008, 2011). These data suggest that the main
mechanism of action of thanatin occurring at MIC concentration
is the disassembly of the Lpt machinery and consequently the
blocking of LPS transport.
Overall, our results highlight OM biogenesis as an excellent
target for novel antibiotic discovery. Thanatin joins the
increasing list of molecules that disrupt the assembly of the OM
with diverse mechanisms (Hart et al., 2019; Imai et al., 2019;
Lehman and Grabowicz, 2019; Psonis et al., 2019). Based on their
mechanisms, these compounds could be employed not only to
fight multidrug resistant pathogens but also in combination with
existing antibiotics not sufficiently effective.
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